Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Receivables (2016 - 2025)

Abeona Therapeutics (ABEO) has 13 years of Receivables data on record, last reported at $5.6 million in Q2 2023.

  • For Q2 2023, Receivables rose 66.22% year-over-year to $5.6 million; the TTM value through Jun 2023 reached $5.6 million, up 66.22%, while the annual FY2021 figure was $6.0 million, N/A changed from the prior year.
  • Receivables reached $5.6 million in Q2 2023 per ABEO's latest filing, down from $27.3 million in the prior quarter.
  • Across five years, Receivables topped out at $27.3 million in Q3 2022 and bottomed at $15000.0 in Q3 2019.
  • Average Receivables over 5 years is $7.1 million, with a median of $4.5 million recorded in 2022.
  • Peak YoY movement for Receivables: plummeted 99.73% in 2019, then soared 93233.33% in 2020.
  • A 5-year view of Receivables shows it stood at $15000.0 in 2019, then skyrocketed by 93233.33% to $14.0 million in 2020, then crashed by 57.14% to $6.0 million in 2021, then surged by 355.78% to $27.3 million in 2022, then plummeted by 79.52% to $5.6 million in 2023.
  • Per Business Quant database, its latest 3 readings for Receivables were $5.6 million in Q2 2023, $27.3 million in Q3 2022, and $3.4 million in Q2 2022.